University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA.
National Jewish Health, Division of Pulmonary, Critical Care and Sleep Medicine, Denver, CO, USA.
Curr Opin Pharmacol. 2022 Aug;65:102245. doi: 10.1016/j.coph.2022.102245. Epub 2022 Jun 1.
Interstitial lung disease (ILD) is a common manifestation in connective tissue diseases (CTD), such as rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myositis (IM). ILD is associated with significant morbidity and mortality in nearly all CTD highlighting the critical need for effective treatment strategies in this patient population. In this review, we will summarize the approach to treatment when there is concern for CTD-ILD and highlight recent advancements in therapeutics within various forms of CTD-ILD.
间质性肺疾病（ILD）是结缔组织疾病（CTD）的常见表现，如类风湿关节炎（RA）、系统性硬皮病（SSc）和炎性肌病（IM）。ILD 在几乎所有 CTD 患者中都与显著的发病率和死亡率相关，这突出表明在这一患者群体中需要有效的治疗策略。在这篇综述中，我们将总结当有 CTD-ILD 时的治疗方法，并重点介绍各种形式的 CTD-ILD 中治疗方法的最新进展。
